Advisory Committee on Immunization Practices, 66029-66030 [2016-23053]

Download as PDF Federal Register / Vol. 81, No. 186 / Monday, September 26, 2016 / Notices Leroy A. Richardson, Chief, Information Collection Review Office, Office of Scientific Integrity, Office of the Associate Director for Science, Office of the Director, Centers for Disease Control and Prevention. [FR Doc. 2016–23073 Filed 9–23–16; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS) Centers for Disease Control and Prevention (CDC) Breast and Cervical Cancer Early Detection and Control Advisory Committee (BCCEDCAC): Notice of Charter Renewal This gives notice under the Federal Advisory Committee Act (Pub. L. 92– 463) of October 6, 1972, that the charter for the Breast and Cervical Cancer Early Detection and Control Advisory Committee, Department of Health and Human Services, has been renewed for a 2-year period through September 12, 2018. For information, contact Ms. Jameka Blackmon, Designated Federal Officer, BCCEDCAC, CDC, 1600 Clifton Road NE., M/S K57, Atlanta, Georgia, 30329, telephone (770) 488–4740; fax (770) 488–3230. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. Elaine L. Baker, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. 2016–23057 Filed 9–23–16; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES mstockstill on DSK3G9T082PROD with NOTICES Centers for Disease Control and Prevention Disease, Disability, and Injury Prevention and Control Special Emphasis Panel: Notice of Charter Renewal This gives notice under the Federal Advisory Committee Act (Pub. L. 92– 463) of October 6, 1972, that the charter for the Disease, Disability, and Injury Prevention and Control Special Emphasis Panel, Centers for Disease VerDate Sep<11>2014 19:40 Sep 23, 2016 Jkt 238001 Control and Prevention, Department of Health and Human Services, has been renewed for a 2-year period through September 18, 2018. For information, contact M. Chris Langub, Ph.D., Designated Federal Officer, Disease, Disability, and Injury Prevention and Control Special Emphasis Panel, Centers for Disease Control and Prevention, Department of Health and Human Services, 1600 Clifton Road NE., Mailstop K48, Atlanta, Georgia 30329, telephone (770) 488– 3585 or fax (770) 488–4887. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. Elaine L. Baker, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. 2016–23054 Filed 9–23–16; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Initial Review In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces a meeting for the initial review of applications in response to PAR 13–129, Occupational Safety and Health Research, NIOSH Member Conflict Review. Time and Date: 1:00 p.m.–5:00 p.m., EDT, October 20, 2016 (Closed). Place: Teleconference. Status: The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92– 463. Matters for Discussion: The meeting will include the initial review, discussion, and evaluation of applications received in response to ‘‘PAR 13–129, NIOSH Member Conflict Review.’’ Contact Person for More Information: Nina Turner, Ph.D., Scientific Review PO 00000 Frm 00035 Fmt 4703 Sfmt 4703 66029 Officer, NIOSH, CDC, 1095 Willowdale Road, Mailstop G905, Morgantown, West Virginia 26506, Telephone: (304) 285–5976. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. Elaine L. Baker, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. 2016–23056 Filed 9–23–16; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Advisory Committee on Immunization Practices In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following meeting of the aforementioned committee. Time and Date: 8:00 a.m.–6:00 p.m., EDT, October 19, 2016 8:00 a.m.–3:30 p.m., EDT, October 20, 2016 Place: CDC, Tom Harkin Global Communications Center, 1600 Clifton Road NE., Building 19, Kent ‘‘Oz’’ Nelson Auditorium, Atlanta, Georgia 30329. Status: Open to the public, limited only by the space available. Time will be available for public comment. The public is welcome to submit written comments in advance of the meeting. Comments should be submitted in writing by email to the contact person listed below. The deadline for receipt is October 11, 2016. All written comments must contain the name, address, and organizational affiliation of the speaker, as well as the topic being addressed. Written comments should not exceed one single-spaced typed page in length and delivered in 3 minutes or less. Please note that the public comment period may end before the time indicated, following the last call for comments. Members of the public who wish to provide public comments should plan to attend the public comment session at the start time listed. Written comments received in advance E:\FR\FM\26SEN1.SGM 26SEN1 mstockstill on DSK3G9T082PROD with NOTICES 66030 Federal Register / Vol. 81, No. 186 / Monday, September 26, 2016 / Notices of the meeting will be included in the official record of the meeting. The meeting will be webcast live via the World Wide Web; for instructions and more information on ACIP please visit the ACIP Web site: http:// www.cdc.gov/vaccines/acip/index.html. Purpose: The committee is charged with advising the Director, CDC, on the appropriate use of immunizing agents. In addition, under 42 U.S.C. §1396s, the committee is mandated to establish and periodically review and, as appropriate, revise the list of vaccines for administration to vaccine-eligible children through the Vaccines for Children (VFC) program, along with schedules regarding the appropriate periodicity, dosage, and contraindications applicable to the vaccines. Further, under provisions of the Affordable Care Act, at section 2713 of the Public Health Service Act, immunization recommendations of the ACIP that have been adopted by the Director of the Centers for Disease Control and Prevention and appear on the CDC immunization schedules must be covered by applicable health plans. Matters for Discussion: The agenda will include discussions on: Meningococcal vaccines; human papillomavirus vaccines; influenza; hepatitis vaccines; pertussis vaccines; Respiratory Syncytial Virus (RSV); child and adolescent immunization schedule; adult immunization schedule; herpes zoster vaccine; yellow fever vaccine; pneumococcal vaccine and vaccine supply. A recommendation vote is scheduled for Hepatitis B vaccine, pertussis vaccine, human papillomavirus vaccines, meningococcal vaccines, child and adolescent immunization schedule, and adult immunization schedule. A Vaccines for Children (VFC) vote is scheduled for human papillomavirus vaccines, Hepatitis B vaccine and meningococcal vaccines. Agenda items are subject to change as priorities dictate. Contact Person for More Information: Stephanie Thomas, National Center for Immunization and Respiratory Diseases, CDC, 1600 Clifton Road NE., MS–A27, Atlanta, Georgia 30329, Telephone: (404) 639–8836; Email: ACIP@ CDC.GOV. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities for both the Centers for Disease Control and VerDate Sep<11>2014 19:40 Sep 23, 2016 Jkt 238001 Prevention and the Agency for Toxic Substances and Disease Registry. Prevention and the Agency for Toxic Substances and Disease Registry. Elaine L. Baker, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. Elaine L. Baker, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. 2016–23053 Filed 9–23–16; 8:45 am] [FR Doc. 2016–23055 Filed 9–23–16; 8:45 am] BILLING CODE 4160–18–P BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Initial Review In accordance with Section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces a meeting for the initial review of applications in response to Funding Opportunity Announcement (FOA) GH16–007, Operations Research (Implementation Science) for Strengthening Global Health Protection Implementation. Times and dates: 9:00 a.m.–2:00 p.m., EDT, Panel A, October 18, 2016 (Closed); 9:00 a.m.–2:00 p.m., EDT, Panel B, October 19, 2016 (Closed). Place: Teleconference. Status: The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92– 463. Matters for discussion: The meeting will include the initial review, discussion, and evaluation of applications received in response to GH16–007 Operations Research (Implementation Science) for Strengthening Global Health Protection Implementation. Contact person for more information: Hylan Shoob, Scientific Review Officer, Center for Global Health (CGH) Science Office, CGH, CDC, 1600 Clifton Road NE., Mailstop D–69, Atlanta, Georgia 30329, Telephone: (404) 639–4796. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and PO 00000 Frm 00036 Fmt 4703 Sfmt 4703 DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention [30Day–16–0457] Agency Forms Undergoing Paperwork Reduction Act Review The Centers for Disease Control and Prevention (CDC) has submitted the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995. The notice for the proposed information collection is published to obtain comments from the public and affected agencies. Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should address any of the following: (a) Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; (b) Evaluate the accuracy of the agencies estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (c) Enhance the quality, utility, and clarity of the information to be collected; (d) Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submission of responses; and (e) Assess information collection costs. To request additional information on the proposed project or to obtain a copy of the information collection plan and instruments, call (404) 639–7570 or send an email to omb@cdc.gov. Written comments and/or suggestions regarding the items contained in this notice should be directed to the Attention: CDC Desk Officer, Office of Management and Budget, Washington, DC 20503 or by fax to (202) 395–5806. Written E:\FR\FM\26SEN1.SGM 26SEN1

Agencies

[Federal Register Volume 81, Number 186 (Monday, September 26, 2016)]
[Notices]
[Pages 66029-66030]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-23053]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Advisory Committee on Immunization Practices

    In accordance with section 10(a)(2) of the Federal Advisory 
Committee Act (Pub. L. 92-463), the Centers for Disease Control and 
Prevention (CDC) announces the following meeting of the aforementioned 
committee.
    Time and Date:
8:00 a.m.-6:00 p.m., EDT, October 19, 2016
8:00 a.m.-3:30 p.m., EDT, October 20, 2016
    Place: CDC, Tom Harkin Global Communications Center, 1600 Clifton 
Road NE., Building 19, Kent ``Oz'' Nelson Auditorium, Atlanta, Georgia 
30329.
    Status: Open to the public, limited only by the space available. 
Time will be available for public comment. The public is welcome to 
submit written comments in advance of the meeting. Comments should be 
submitted in writing by email to the contact person listed below. The 
deadline for receipt is October 11, 2016. All written comments must 
contain the name, address, and organizational affiliation of the 
speaker, as well as the topic being addressed. Written comments should 
not exceed one single-spaced typed page in length and delivered in 3 
minutes or less. Please note that the public comment period may end 
before the time indicated, following the last call for comments. 
Members of the public who wish to provide public comments should plan 
to attend the public comment session at the start time listed. Written 
comments received in advance

[[Page 66030]]

of the meeting will be included in the official record of the meeting.
    The meeting will be webcast live via the World Wide Web; for 
instructions and more information on ACIP please visit the ACIP Web 
site: http://www.cdc.gov/vaccines/acip/index.html.
    Purpose: The committee is charged with advising the Director, CDC, 
on the appropriate use of immunizing agents. In addition, under 42 
U.S.C. Sec. 1396s, the committee is mandated to establish and 
periodically review and, as appropriate, revise the list of vaccines 
for administration to vaccine-eligible children through the Vaccines 
for Children (VFC) program, along with schedules regarding the 
appropriate periodicity, dosage, and contraindications applicable to 
the vaccines. Further, under provisions of the Affordable Care Act, at 
section 2713 of the Public Health Service Act, immunization 
recommendations of the ACIP that have been adopted by the Director of 
the Centers for Disease Control and Prevention and appear on the CDC 
immunization schedules must be covered by applicable health plans.
    Matters for Discussion: The agenda will include discussions on: 
Meningococcal vaccines; human papillomavirus vaccines; influenza; 
hepatitis vaccines; pertussis vaccines; Respiratory Syncytial Virus 
(RSV); child and adolescent immunization schedule; adult immunization 
schedule; herpes zoster vaccine; yellow fever vaccine; pneumococcal 
vaccine and vaccine supply. A recommendation vote is scheduled for 
Hepatitis B vaccine, pertussis vaccine, human papillomavirus vaccines, 
meningococcal vaccines, child and adolescent immunization schedule, and 
adult immunization schedule. A Vaccines for Children (VFC) vote is 
scheduled for human papillomavirus vaccines, Hepatitis B vaccine and 
meningococcal vaccines. Agenda items are subject to change as 
priorities dictate.
    Contact Person for More Information: Stephanie Thomas, National 
Center for Immunization and Respiratory Diseases, CDC, 1600 Clifton 
Road NE., MS-A27, Atlanta, Georgia 30329, Telephone: (404) 639-8836; 
Email: ACIP@CDC.GOV.
    The Director, Management Analysis and Services Office, has been 
delegated the authority to sign Federal Register notices pertaining to 
announcements of meetings and other committee management activities for 
both the Centers for Disease Control and Prevention and the Agency for 
Toxic Substances and Disease Registry.

Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease 
Control and Prevention.
[FR Doc. 2016-23053 Filed 9-23-16; 8:45 am]
 BILLING CODE 4160-18-P